Premium
mdm 2 mRNA expression is associated with survival in ovarian cancer
Author(s) -
Tanner Berno,
Hengstler Jan Georg,
Laubscher Silke,
Meinert Rolf,
Oesch Franz,
Weikel Wolfgang,
Knapstein Paul Georg,
Becker Roger
Publication year - 1997
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19970822)74:4<438::aid-ijc13>3.0.co;2-5
Subject(s) - ovarian cancer , carboplatin , cisplatin , chemotherapy , cyclophosphamide , messenger rna , oncology , biology , cancer , cancer research , ovary , medicine , gene , biochemistry
Expression of mdm ‐2 mRNA was measured in 90 ovarian‐cancer tissue specimens using the S1 nuclease assay, to investigate a possible association between MDM2 expression and prognosis. mdm ‐2 mRNA expression was an independent prognostic factor for patients with primary ovarian cancer, FIGO (International Federation of Gynecology and Obstetrics) stages III and IV (n = 57), who all received chemotherapy with carboplatin or cisplatin and cyclophosphamide. Median survival time for patients (FIGO stages III and IV) with no detectable expression of mdm ‐2 mRNA (n = 14) was 171 days, as compared with 839 days for patients (n = 43) with detectable mdm ‐2 mRNA ( p = 0.0194; log‐rank test). However, no association between mdm ‐2 mRNA expression and survival was observed for patients with FIGO stages I and II who did not receive chemotherapy. mdm ‐2 expression was not associated with FIGO stage, residual disease, histologic grade and type. Our results suggest that mdm ‐2, which is known to disrupt p53 function, sensitizes ovarian‐cancer cells to cisplatin/cyclophosphamide, possibly by inhibition of p53 ‐mediated G 1 cell‐cycle arrest and p53 ‐stimulated nucleotide‐excision repair. Int. J. Cancer 74:438–442, 1997. © 1997 Wiley‐Liss, Inc.